Skip to content

Epidaurus · Treatment Guide · Therapeutic Interventions

Going abroad for —

Chemotherapy & Immunotherapy Quality

Systemic cancer treatment quality including chemotherapy, immunotherapy, and targeted therapy

The country comparison

Which countries are best for chemotherapy & immunotherapy quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 South Korea KR 5.0/5 Good South Korea demonstrates excellent chemotherapy and immunotherapy quality with all Score 5 criteria met. The country operates multiple internationally accredited cancer centers, provides comprehensive access to modern... Full report
    The evidence behind this score 8 cited points
    • 5-year cancer survival rate of 72.9% (2018-2022) exceeds Score 5 thresholds of >80% early-stage and >65% advanced cancers
    • 29 JCI-accredited hospitals with 4 government-designated CAR-T therapy centers operationally active
    • 504 board-certified medical oncologists with international training documented in USA, Europe, and Japan
    • Stomach cancer 5-year survival of 77% is 2-3 times higher than USA (32.4%) and UK (21.6%), demonstrating specialized excellence
    • Comprehensive immunotherapy access: Pembrolizumab approved 2015 for 6+ cancer types, Nivolumab for 10+ types, CAR-T therapies reimbursed nationally since April 2022
    • Rapid CAR-T manufacturing: Seoul National University Hospital reduced production time to 12 days versus standard 4-8 weeks
    • 1.17 million international cancer patients in 2024 supported by multilingual staff and JCI-accredited facilities
    • Asan Medical Center's precision medicine leadership: performs 50% of South Korea's NGS, operates 300+ clinical trials annually, maintains half-million sample biobank

    Read the full South Korea report →

  2. 2 Israel IL 5.0/5 Good Israel demonstrates exceptional systemic cancer treatment capabilities across all rubric dimensions. Multiple internationally accredited centers (Sheba ranked in Newsweek's top 10 oncology hospitals for 7 consecutive ... Full report
    The evidence behind this score 5 cited points
    • Sheba Medical Center ranked in Newsweek's top 10 global hospitals for oncology for seven consecutive years; operates largest CAR-T center in Europe with 258 patients treated since 2016
    • Rambam Health Care Campus and Davidoff Cancer Center hold ESMO Designated Centre of Integrated Oncology and Palliative Care status
    • Breast cancer 5-year survival 90.7% for patients ages 18-59 (2009-2018 diagnosis) with statistically significant improvement trend; prostate cancer 92% 5-year effectiveness
    • Three hospitals (Sheba, Hadassah, Ichilov) hold in-house CAR-T therapy approvals from Helsinki Committee and Israeli Ministry of Health; multiple precision medicine and AI-guided oncology programs operational
    • All major cancer centers maintain dedicated international patient departments with multilingual staff (English, Arabic, Russian, French, German, Spanish) and end-to-end care coordination; costs reported as 50-75% lower than U.S./UK

    Read the full Israel report →

  3. 3 Singapore SG 5.0/5 Good Singapore demonstrates all hallmarks of a Score 5 facility with multiple internationally accredited cancer centers (NCCS ranked 6th in Asia-Pacific for oncology by Newsweek 2025), comprehensive systemic therapy availa... Full report
    The evidence behind this score 5 cited points
    • NCCS JCI-accreditation and Newsweek Asia-Pacific Top 6 ranking in oncology (2025); multiple private hospitals also JCI-accredited
    • Full checkpoint inhibitor portfolio (pembrolizumab, nivolumab, atezolizumab, ipilimumab, relatlimab) and CAR-T cell therapy approved 2021 (first in Southeast Asia) for ALL, DLBCL, myeloma
    • Five-year survival rates exceed international benchmarks: breast 84.2%, prostate 90.3%, colorectal 64.2% (2019-2023)
    • 161 registered medical oncologists with mandatory 6-year ACGME-I accredited residency and SAB certification; international fellowships available
    • CanHOPE multilingual support in ~20 global cities with direct insurer billing; 646,000 international patients in 2024; 220+ ongoing Phase I-IV clinical trials providing access to experimental therapies

    Read the full Singapore report →

  4. 4 Germany DE 5.0/5 Good Germany comprehensively meets all Score 5 criteria with a mature, three-tier infrastructure of 2,159 DKG-certified facilities including 15 comprehensive cancer centers backed by world-class research hubs (DKFZ, NCT He... Full report
    The evidence behind this score 5 cited points
    • 2,159 DKG-certified cancer facilities (as of December 2024) including 15 CCCs; mandatory multidisciplinary tumor boards at all certified centers [Zertifizierung - Deutsche Krebsgesellschaft - 2024]
    • Five-year survival rates exceed international benchmarks: breast cancer 86% (EU average 82%), colon cancer 64.8% (OECD 62.1%), prostate cancer 91–94% early-stage, childhood ALL 91.8% [EU Country Cancer Profile Germany 2025 - OECD - 2025]
    • Drug access speed of 133 days from EMA authorization to patient availability — fastest in Europe under AMNOG system [Impact of AMNOG on launch delays - PMC - 2023]
    • CAR-T cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel, BCMA-directed) available at ≥5 university centers and covered by statutory health insurance [CAR-T Cell Therapy in Germany - car-t-access.org - 2024]
    • Comprehensive medical tourism infrastructure with dedicated international patient offices at Charité, LMU Munich, and Heidelberg; 24/7 English interpretation; appointments coordinated within 24 hours [Cancer Treatment in Germany for Foreigners - Cancer Rounds - 2024]

    Read the full Germany report →

  5. 5 United States US 5.0/5 Good The United States demonstrates exceptional excellence in chemotherapy and immunotherapy quality, meeting or exceeding all Score 5 criteria. With 73 NCI-Designated Cancer Centers offering comprehensive systemic therapy... Full report
    The evidence behind this score 6 cited points
    • 73 NCI-Designated Cancer Centers in 37 states, including 58 Comprehensive Cancer Centers, representing the top 4% of approximately 1,500 cancer centers in the United States, with ~400,000 patients receiving diagnoses annually
    • 6 FDA-approved CAR-T cell therapies as of December 2024, comprehensive immunotherapy portfolio including PD-1, PD-L1, and CTLA-4 inhibitors, and precision medicine programs operational
    • 70% five-year relative survival for all cancers combined (2015-2021), with regional-stage disease at 69% and myeloma at 62%, representing significant improvements from mid-1990s baselines (63%, 54%, and 32% respectively)
    • FDA issued 60+ oncology approvals in 2024 including 11 first-in-class therapeutics, providing rapid patient access to innovations within months of approval
    • NCCN Clinical Practice Guidelines recognized as the global standard for cancer treatment protocols, applied to 97% of US cancer patients and acknowledged as the most thorough and frequently updated guidelines available
    • ABIM board certification as the widely-used standard for medical oncologists, requiring fellowship training in medical oncology plus internal medicine certification, with NCI centers serving as centers for scientific leadership and international research collaborations

    Read the full United States report →

  6. 6 United Arab Emirates AE 4.5/5 Good The UAE demonstrates excellent systemic cancer treatment capabilities at tier-one centers, with breast cancer 5-year survival at 89% exceeding international benchmarks (>80%). Multiple internationally accredited cente... Full report
    The evidence behind this score 5 cited points
    • Breast cancer 5-year survival at 89%, comparable to Australia (89.5%) and Canada (88.2%), exceeding Score 5 threshold of >80%
    • Multiple internationally accredited centers including ESMO-accredited Burjeel Cancer Institute with JCI, TEMOS, CAP, CARF, EBMT, and ISO 9001:2015 certifications
    • CAR-T cell therapy domestically manufactured at ADSCC (FACT-accredited April 2024) and Burjeel (2025), with precision medicine and tumor biomarker testing at leading centers
    • Newly approved FDA/EMA drugs available within 12-18 months via EDE 25-working-day fast-track approval pathway
    • TEMOS-accredited medical tourism programs with multilingual oncology teams and concierge services; international patients from Saudi Arabia, Kuwait, India, Nigeria, Ethiopia, Russia, and Kazakhstan

    Read the full United Arab Emirates report →

  7. 7 Spain ES 4.5/5 Good Spain combines world-leading CAR-T infrastructure (Europe's first domestically manufactured, AEMPS-approved therapies) with multiple internationally accredited oncology centers and excellent 5-year survival rates (bre... Full report
    The evidence behind this score 6 cited points
    • Spain operates 28 AEMPS-accredited CAR-T centers with Hospital Clínic treating >500 patients and achieving 90% response rate in ALL, 60% in myeloma
    • Two OECI-accredited Comprehensive Cancer Centres (Vall d'Hebron and Clínic Barcelona) with 18 OECI-member institutions total
    • 5-year survival rates: breast cancer 85.5%, prostate 89.6%, colorectal 65% (colorectal exceeds EU-24 average of 60%)
    • Led EU with 336 oncology clinical trials authorized in 2024, providing access to novel agents before formal EMA approval
    • Hospital-developed CAR-T (ARI-0001, ARI-0002h) cost under €90,000 versus ~€400,000 commercial alternatives
    • Established medical tourism programs: MD Anderson Madrid (only European affiliate), Hospital Ruber Internacional (24/7 multilingual, IMTJ award), Clínica Universidad de Navarra (JCI since 2004, Newsweek Top 35)

    Read the full Spain report →

  8. 8 Japan JP 4.5/5 Good Japan exhibits world-class cancer treatment infrastructure, outcomes, and oncology expertise exceeding Score 5 standards across most dimensions—408 designated cancer care hospitals, 1,604 certified medical oncologists... Full report
    The evidence behind this score 6 cited points
    • 408 designated cancer care hospitals with mandated chemotherapy centers; NCC Hospital East holds ESMO Centre of Integrated Oncology designation; NCC Hospital named 'World's Best Specialized Hospitals 2021' by Newsweek
    • Comprehensive approved therapies: multiple checkpoint inhibitors (nivolumab, pembrolizumab, durvalumab, ipilimumab, atezolizumab), full range of targeted therapies (ALK/EGFR/RET/MET/KRAS/HER2 inhibitors, antibody-drug conjugates), and all three FDA-approved CAR-T therapies (Kymriah, Yescarta, Abecma)
    • 1,604 JSMO-certified medical oncologists as of 2022, up from 867 in 2013; structured 3-year fellowships with international training; 53.7% of DCCHs have dedicated medical oncology departments with JSMO-certified specialists
    • Five-year survival rates: breast 87.5%, prostate 99.2%, colorectal 69.7%; CONCORD-3 study shows stomach cancer 60.3% net survival (2010-14), improving from 50.5% (2000-04), outperforming Western peers
    • National cancer genomic medicine program across 260 hospitals with insurance-reimbursed comprehensive genomic profiling; C-CAT datacenter provides standardized expert panel recommendations; 45-59% of advanced patients have actionable mutations detected
    • Formal international patient programs at NCC Hospital through seven coordinating agencies offering multilingual support; median drug approval lag of 1,278 days post-US approval (2011-2022 historical data) but shorter for immunotherapy and narrowing with recent PMDA reforms

    Read the full Japan report →

  9. 9 Poland PL 4.0/5 Good Poland operates multiple internationally accredited cancer centers anchored by MSCNRIO's ESMO-designated flagship institutions, offering comprehensive chemotherapy, reimbursed checkpoint inhibitors, targeted therapies... Full report
    The evidence behind this score 5 cited points
    • MSCNRIO Warsaw holds ESMO Designated Centre status, manages 25% of Polish cancer patients with 650+ clinical trials; Gliwice branch operates a Molecular Laboratory recognized as Centre of Excellence with 120+ past clinical trials
    • Multiple checkpoint inhibitors reimbursed since 2018 (nivolumab, pembrolizumab) with 63 new oncology indications added to reimbursement list in 2025; standard chemotherapy universally available under NFZ
    • Breast cancer 5-year survival 80% and prostate cancer 85.2% meet international benchmarks; overall national rate 42.7% vs. EU 54.6%; documented improving trend across major cancer types
    • Median 27-month delay from EMA approval to reimbursement; precision medicine integration via Oncotype DX (changed treatment decisions in 44.3% of patients), NGS-based molecular profiling, and mandatory multidisciplinary tumor boards at SOLO II/III centers
    • Private medical tourism centers (Carolina Medical Center, KCM Clinic ISO-certified, Medicover) offer English-language oncology services at 50-80% below US costs with organized international patient coordination

    Read the full Poland report →

  10. 10 United Kingdom GB 4.0/5 Good The UK demonstrates world-class cancer infrastructure with multiple internationally accredited centers (The Christie as OECI Comprehensive Cancer Centre, Royal Marsden CQC Outstanding), comprehensive systemic therapy ... Full report
    The evidence behind this score 5 cited points
    • The Christie re-accredited as OECI Comprehensive Cancer Centre in February 2025 (status to July 2030); Royal Marsden rated 'Outstanding' by Care Quality Commission
    • Cancer Drugs Fund provides access to 100+ drugs across 250 indications approximately 6 months faster than standard regulatory processes; NICE-approved CAR-T (obe-cel) achieved 74.7% remission rate in 127 patients with relapsed/refractory B-ALL
    • Overall 5-year cancer survival improved from 47.9% (2005 cohort) to 55.7% (2016 cohort); prostate cancer 88.5%, melanoma 92.6%, testicular 93.5%, but lung and stomach cancer rank 28th of 33 comparable nations with combined 16% survival
    • Medical oncologists complete 2-year MRCP training plus 4-year specialty training with mandatory Specialty Certificate Examination; however, 15% deficit in clinical oncologists in 2024, projected to reach 19% by 2029
    • Comprehensive private medical tourism infrastructure through Royal Marsden Private Care, HCA Healthcare UK, London Clinic, and Cromwell Hospital with multilingual support and dedicated international patient services; 810,000 genomic tests in 2024 integrating precision medicine into routine care

    Read the full United Kingdom report →

  11. 11 Thailand TH 4.0/5 Good Thailand demonstrates strong systemic cancer treatment capabilities with multiple JCI-accredited centers, internationally trained medical oncologists, and comprehensive chemotherapy, immunotherapy, and targeted therap... Full report
    The evidence behind this score 7 cited points
    • Multiple JCI-accredited centers including Samitivej, Bumrungrad, and Bangkok Hospital's Wattanosoth Cancer Hospital with comprehensive systemic therapy programs
    • Thai oncologists trained internationally at Harvard, Oxford, and University of Toronto with certifications from American Board of Internal Medicine or European Society for Medical Oncology
    • CAR-T cell manufacturing capabilities operational at Siriraj Hospital (GMP-compliant closed system with nine clinical-grade products) and Cell and Gene Therapy Manufacturing Center at Chulalongkorn University (first FDA-certified facility in Thailand)
    • Nivolumab and pembrolizumab checkpoint inhibitors approved by both US and Thai FDA; genetic testing available in 1 week for single-gene and 3 weeks for NGS gene panels
    • Colorectal cancer 5-year survival rates for advanced stages below 50% (below international 65% threshold for advanced treatable cancers); breast cancer 5-year survival in Northeast Thailand 42.9% (significantly below international standards), though overall breast cancer survival approximately 80%
    • Access disparities: high-cost immunotherapy and targeted therapy available primarily to private-pay patients; public insurance schemes lack reimbursement coverage with approval lags of 2-3+ years behind international approval
    • Extensive medical tourism infrastructure with 520,000+ international patients at Bumrungrad annually, multilingual support in 20+ languages, and ranking as #5 global medical tourism destination

    Read the full Thailand report →

  12. 12 Brazil BR 4.0/5 Good Brazil's elite private cancer centers in São Paulo rank among the world's best, with Hospital Israelita Albert Einstein and Hospital Sírio-Libanês placing in the global top 20 for oncology and offering comprehensive s... Full report
    The evidence behind this score 5 cited points
    • Hospital Israelita Albert Einstein and Hospital Sírio-Libanês ranked #19 and #20 globally in oncology by Newsweek 2025
    • ANVISA approved 68 of 104 FDA oncology drugs (2008–2023) with 558-day median approval lag; pembrolizumab has 36 ANVISA approvals but only 1 covered by public health system
    • 5-year breast cancer survival: 80.6% in private sector (exceeds >80% international benchmark), 68.5% in public sector; gastric cancer improved from 27.8% to 53.9% at major centers
    • Hospital Sírio-Libanês International Patient Service Center provides services in 4 languages and coordinates with 70+ international insurers; Brazilian treatment costs 50–70% lower than US equivalents
    • CAR-T therapy remains investigational and trial-based; INCA-CHOP partnership and local manufacturing initiatives underway but not yet operationally available as routine service; geographic concentration creates systemic access barriers with only 4% of cancer centers in the North

    Read the full Brazil report →

  13. 13 Malaysia MY 4.0/5 Good Malaysia's private oncology sector meets the 'Good' (Score 4) standard with multiple internationally accredited centers (ESMO Designated, ACHSI Centre of Excellence, Mayo Clinic network partners), comprehensive system... Full report
    The evidence behind this score 6 cited points
    • Multiple internationally accredited centers: Beacon Hospital and Sunway Cancer Centre hold ESMO Designated Centre status; SJMC is the first Asia-Pacific hospital with ACHSI Centre of Excellence certification for oncology; KPJ Damansara joined Mayo Clinic Care Network (February 2024) for live multidisciplinary case conferences
    • Comprehensive systemic therapy availability: Standard chemotherapy (platinum, anthracyclines, taxanes), targeted therapies (HER2, EGFR), and immune checkpoint inhibitors (pembrolizumab, nivolumab) available at private centers; ICIs not covered by government UHC but accessible in private sector
    • Well-trained oncology workforce: 184 oncologists as of 2025; private hospital physicians hold FRCR (UK) credentials and complete international fellowships; Master of Clinical Oncology program established since 2002
    • Mixed survival outcomes: One tertiary hospital reports 46.5% five-year colorectal cancer survival; breast cancer 88% five-year in private sector (exceeds early-stage benchmarks); national figures artificially depressed by late-stage diagnosis (60%+ at stages III-IV)
    • Excellent medical tourism infrastructure: 1.85 million medical tourists in 2025; Prince Court serves 140+ nationalities with multilingual coordinators; comprehensive support (airport transfers, visa assistance, hotel partnerships, currency exchange, post-departure telemedicine)
    • Innovation in CAR-T and precision medicine: Domestically manufactured CAR-T at UKM delivered 100% complete response in B-ALL with 0% neurotoxicity; GMP CAR-T laboratory opened at UMMC April 2024; NGS precision oncology embedded at major centers (SJMC, Klang Valley hospitals)

    Read the full Malaysia report →

  14. 14 India IN 3.5/5 Moderate India demonstrates strong systemic cancer treatment capabilities at flagship centers (Tata Memorial, Apollo, Fortis, Max) with comprehensive chemotherapy, immunotherapy including CAR-T products, targeted therapy, and ... Full report
    The evidence behind this score 8 cited points
    • CAR-T cell therapy: NexCAR19 approved October 2023 (first domestically-developed CAR-T in LMIC), available at 30+ hospitals across 10+ cities at ~$50,000 vs $400,000 in US; second CAR-T product Qartemi also approved
    • JCI accreditation: India has 55 JCI-accredited hospitals; Apollo achieved 7th JCI reaccreditation March 2024; Apollo Proton Cancer Centre 2nd JCI reaccreditation June 2023
    • Survival rates: Hospital-based at TMH 70%+ overall cure rates and 65% 5-year oral cancer survival; population-level breast cancer 66.1% (below Score 4's 70-80% threshold but approaching); blood cancer remission 60-70%
    • Medical oncology training: Well-structured 3-year DM super-specialty requiring MD/DNB completion and NEET-SS national entrance; many oncologists trained at US, UK, or European institutions
    • Precision medicine operational: FoundationOne CDx NGS available, Apollo's molecular tumor boards established, ctDNA liquid biopsy offered at Tata Memorial since 2020
    • Medical tourism infrastructure: Dedicated international patient departments at major centers, fluent English-speaking oncologists, 60-80% cost savings vs Western countries, listed as top destination for African cancer patients
    • Checkpoint inhibitor access limitation: Despite availability since 2015, only 2.83% of eligible patients received immunotherapy at major tertiary center (6.6% private patients vs 0.29% low-income patients showing 23-fold disparity)
    • Oncologist shortage: Approximately 1 medical oncologist per 1 million population vs 161 per million in US; systemic therapy often delivered by non-specialists outside major centers

    Read the full India report →

  15. 15 Hungary HU 3.5/5 Moderate Hungary operates the only OECI-accredited Comprehensive Cancer Center in Central and Eastern Europe with ESMO-aligned protocols and mandatory multidisciplinary tumor boards, supported by modern immunotherapy agents (p... Full report
    The evidence behind this score 6 cited points
    • NIO is the first and only OECI-accredited Comprehensive Cancer Center in Central and Eastern Europe with ESGO accreditation for gynecological oncology and Breast Centres Network membership
    • CAR-T cell therapy is not systematically reimbursed in Hungary with median access time of 52.3 months—among the slowest in Europe; Hungary and Malta are the only EU member states without systematic CAR-T reimbursement
    • Pembrolizumab (Keytruda) automatic reimbursement covers only 38.5% of EU-approved indications versus EU average of 59%; individual approval process averages 36 days but can reach 441 days
    • 5-year net survival improved 2011–2019 across all major cancer types: breast 86.84%, prostate 89.76%, colorectal 59.78%, lung 23.55%—exceeding Score 3 for early-stage but falling below Score 4 for advanced cancers
    • Hungary's National Molecular Tumor Board evaluates 10–15 comprehensive genomic profiling cases weekly with 45% showing clinically actionable alterations; NGS available at NIO, Semmelweis University, and University of Pécs
    • Medical tourism infrastructure includes 2,094 coordinated oncology cases via Bookimed, English and German-speaking oncology staff at major facilities, and treatment costs 35–60% below Western European levels

    Read the full Hungary report →

  16. 16 Jordan JO 3.5/5 Moderate Jordan demonstrates world-class infrastructure and expertise at KHCC with exceptional early-stage cancer survival rates (96% for breast stage I), well-trained medical oncologists with international fellowship experien... Full report
    The evidence behind this score 9 cited points
    • KHCC early-stage breast cancer survival exceeds international benchmarks: 96% (stage I), 91.3% (stage II), 75.7% (stage III)
    • KHCC holds JCI disease-specific cancer center accreditation (first in developing world, sixth globally), MAGNET nursing accreditation, and CAP accreditation
    • Medical oncology fellows ranked first among North American-affiliated programs in 2019 ASCO examination; international rotations at MD Anderson, Princess Margaret, Leeds Cancer Centre
    • Advanced NSCLC immunotherapy median overall survival 11.8 months (244 patients 2017-2022), substantially below 16-20+ month trial benchmarks; 21% died within 3 months of initiating treatment
    • Single institution dependence: KHCC handles 60%+ of Jordan's cancer cases; comprehensive systemic oncology (immunotherapy programs, precision medicine, multidisciplinary tumor boards) essentially unavailable outside KHCC
    • CAR-T cell therapy listed as goal but not yet operational; GMP laboratory establishment and CAR-T initiation are stated objectives only
    • HTA program approved >70% of novel cancer drug requests after price negotiations; pembrolizumab and nivolumab available
    • Dedicated medical tourism infrastructure: 224,000+ medical tourists to Jordan in 2024; 25-40% cost advantage vs. US/Europe; multilingual support (English, French, Kurdish, Arabic); telemedicine follow-up
    • NGS costs approximately $2,820 per test (>50% of Jordan's GDP per capita); 19.1% of patients with actionable mutations unable to access matched therapies due to cost/unavailability

    Read the full Jordan report →

  17. 17 Mexico MX 3.5/5 Moderate Mexico demonstrates strong cancer treatment infrastructure in major cities with multiple JCI-accredited centers, standard immunotherapies widely available, and well-developed medical tourism programs. However, drug ap... Full report
    The evidence behind this score 6 cited points
    • Multiple JCI-accredited comprehensive cancer centers in major cities (Mexico City, Monterrey, Tijuana, Guadalajara) with 172 inpatient beds at INCan alone
    • Drug approval delays of 1-3 years behind FDA for new indications and combination therapies, with COFEPRIS requiring more exhaustive phase III data
    • Five-year survival rates: breast cancer 72% overall (90% early-stage, 33% metastatic), colorectal cancer 50% with 80% diagnosed in advanced stages
    • Significant oncologist workforce shortage with approximately 1 medical oncologist per 136,000 Mexicans, below optimal ratios
    • CAR-T therapy pioneering at only 3 institutions (UANL Monterrey, Centro Médico ABC, Hospital Ángeles) with 9 total HSCT-accredited pediatric centers
    • Excellent medical tourism infrastructure with bilingual support, concierge services, and cost savings of 50-70% on cancer treatments

    Read the full Mexico report →

  18. 18 Colombia CO 3.5/5 Moderate Colombia has built genuine advanced cancer treatment infrastructure at leading centers (CTIC, Valle del Lili, Pablo Tobón Uribe, INC) with comprehensive access to chemotherapy, immunotherapy (checkpoint inhibitors app... Full report
    The evidence behind this score 6 cited points
    • CTIC ($400M investment, opened 2022) operates 56 chemotherapy chairs, 12 specialized clinical units, 176 patient rooms, and intensive care backup across Bogotá, Medellín, Cali, and Bucaramanga
    • Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab) approved by INVIMA from 2016–2022; combination chemo-immunotherapy protocols approved 2020+
    • INC OECI member since 2018 and participates in SWOG cooperative trials; Colombia's first in-situ comprehensive genomic profiling program (2023–2024) found actionable mutations in 76.7% of tested cases
    • Breast cancer 5-year survival 70.8–81.1% in Cali (improving trend over 20 years); however, colorectal cancer 45.8%, lung/stomach <25%, childhood cancer 51%—all below high-income benchmarks
    • Approximately 324 medical oncology specialists nationally (deficit of 125–179 to meet international standards); 6 accredited training programs producing only 5–10 graduates annually
    • Six JCI-accredited hospitals with established medical tourism programs; received 200,000+ international patients annually in 2024; Fundación Santa Fe maintains 100+ international agreements

    Read the full Colombia report →

  19. 19 Turkey TR 3.5/5 Moderate Turkey demonstrates strong cancer treatment infrastructure with 50+ JCI-accredited facilities and internationally trained oncologists, achieving excellent outcomes for common early-stage cancers (86% 5-year breast can... Full report
    The evidence behind this score 5 cited points
    • 50+ JCI-accredited clinics with Anadolu Medical Center OECI-accredited (only 30 centers worldwide)
    • Breast cancer 5-year survival 86% exceeds Score 4 benchmark (70-80%), but pancreatic 10.4% and lung cancer 14.9% survival rates fall well below Score 4 standard (50-65% for advanced cancers)
    • No commercial CAR-T therapy available for standard use; ISIKOK-19 remains in clinical trial phase with 72% response rate in pilot study
    • Market authorization timelines exceed FDA/EMA by 50%+ (estimated 2-3 years vs. 18-24 month Score 4 standard); regulatory barriers deterring new drug submissions
    • Excellent medical tourism infrastructure: 1.8 million medical travelers in 2023, 700,000+ international patients annually, multilingual staff, treatment within 3-5 days

    Read the full Turkey report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for chemotherapy & immunotherapy quality, top to bottom. How we score →

  1. 5/5 Excellent

    Multiple internationally accredited cancer centers with comprehensive systemic therapy programs. Full range of chemotherapy, immunotherapy, and targeted therapies available. Medical oncologists with international training and board certification. Survival rates meeting or exceeding international benchmarks (>80% 5-year survival for early-stage cancers, >65% for advanced treatable cancers). Access to newest approved therapies within 12 months of international approval. Established medical tourism programs with multilingual oncology teams. CAR-T therapy and precision medicine programs operational. Treatment protocols following latest NCCN/ESMO guidelines with documented adherence.

  2. 4/5 Good

    Several accredited cancer centers with strong systemic therapy capabilities. Most standard chemotherapy regimens and common immunotherapies available. Well-trained medical oncologists with some international experience. Survival rates approaching international standards (70-80% 5-year for early-stage, 50-65% for advanced cancers). Access to newer therapies within 18-24 months of approval. Good medical tourism infrastructure with some language support. Some precision medicine capabilities. Generally follows international treatment protocols with minor gaps.

  3. 3/5 Moderate

    Basic cancer centers with standard chemotherapy capabilities. Limited immunotherapy options, mostly older checkpoint inhibitors. Medical oncologists with adequate local training but limited international exposure. Survival rates below international averages but improving (60-70% 5-year for early-stage, 35-50% for advanced cancers). Delayed access to newer therapies (2-3 years post-approval). Limited medical tourism infrastructure. Basic treatment protocols followed but not consistently updated. Some targeted therapy options available.

  4. 2/5 Poor

    Few cancer treatment facilities with basic chemotherapy only. Very limited immunotherapy access, mostly experimental. Medical oncologists with minimal specialized training. Poor survival rates significantly below international standards (40-60% 5-year for early-stage, 20-35% for advanced cancers). Very limited access to newer therapies (3+ years delay or unavailable). No organized medical tourism for cancer care. Outdated treatment protocols. Targeted therapy largely unavailable. Frequent treatment interruptions due to drug shortages.

  5. 1/5 Very Poor / Unavailable

    No dedicated cancer treatment centers or oncology specialists. Only basic chemotherapy drugs available sporadically. No trained medical oncologists, treatment provided by general physicians. Survival rates far below international standards (<40% 5-year even for early-stage cancers). No access to modern immunotherapy or targeted treatments. No medical tourism infrastructure for cancer care. No standardized treatment protocols. Patients typically seek treatment abroad for any serious cancer diagnosis.

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source www.cancerindex.org/Thailand Cited in Chemotherapy & Immunotherapy Quality in Thailand
  2. Untitled source www.snuh.org/global/en/about/EN05006003.do Cited in Chemotherapy & Immunotherapy Quality in South Korea
  3. Untitled source academic.oup.com/jjco/article/41/1/10/815681 Cited in Chemotherapy & Immunotherapy Quality in Turkey
  4. Untitled source acibademinternational.com/cancer-treatment-in-turkey-acibadems-multidisciplinary-oncology-team Cited in Chemotherapy & Immunotherapy Quality in Turkey
  5. Untitled source acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35188 Cited in Chemotherapy & Immunotherapy Quality in India
  6. Untitled source acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22788 Cited in Chemotherapy & Immunotherapy Quality in India
  7. Untitled source acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21820 Cited in Chemotherapy & Immunotherapy Quality in United States
  8. Untitled source acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70043 Cited in Chemotherapy & Immunotherapy Quality in United States
  9. Untitled source ascopost.com/issues/december-10-2025/new-fda-approved-oncology-drugs-and-label-updates-between-december-1-2024-and-november-19-2025 Cited in Chemotherapy & Immunotherapy Quality in United States
  10. Untitled source ascopost.com/issues/january-25-2024/generic-drug-shortages-and-essential-cancer-medicines Cited in Chemotherapy & Immunotherapy Quality in India
  11. Untitled source ascopubs.org/doi/10.1200/GO-25-00095 Cited in Chemotherapy & Immunotherapy Quality in Thailand
  12. Untitled source ascopubs.org/doi/10.1200/GO.20.00122 Cited in Chemotherapy & Immunotherapy Quality in India
  13. Untitled source ascopubs.org/doi/10.1200/GO.22.00405 Cited in Chemotherapy & Immunotherapy Quality in India
  14. Untitled source ascopubs.org/doi/10.1200/GO.24.00131 Cited in Chemotherapy & Immunotherapy Quality in India
  15. Untitled source ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.11057 Cited in Chemotherapy & Immunotherapy Quality in India, Chemotherapy & Immunotherapy Quality in Turkey
  16. Untitled source ascopubs.org/doi/10.1200/OP.21.00883 Cited in Chemotherapy & Immunotherapy Quality in India
  17. Untitled source ascopubs.org/doi/10.1200/OP.23.00545 Cited in Chemotherapy & Immunotherapy Quality in India
  18. Untitled source ashpublications.org/bloodadvances/article/9/18/4727/537314/Inequalities-in-CAR-T-cell-therapy-access-for-US Cited in Chemotherapy & Immunotherapy Quality in United States
  19. Untitled source asianhospital.in/medical-tourism-in-india-a-complete-guide-for-international-patients Cited in Chemotherapy & Immunotherapy Quality in India
  20. Untitled source aslifelinecancercare.com/blog/chemotherapy-cost-in-india Cited in Chemotherapy & Immunotherapy Quality in India
  21. Untitled source avicennaint.com/en/targeted-drug-therapy-in-turkey Cited in Chemotherapy & Immunotherapy Quality in Turkey
  22. Untitled source bccr.tums.ac.ir/index.php/bccrj/article/view/440 Cited in Chemotherapy & Immunotherapy Quality in Turkey
  23. Untitled source bdmschina.com/en/specialties/cancer Cited in Chemotherapy & Immunotherapy Quality in Thailand
  24. Untitled source bloodcancerunited.org/resources/newsroom/fda-approves-car-t-cell-therapy-treat-adults-form-acute-leukemia Cited in Chemotherapy & Immunotherapy Quality in United States

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Therapeutic Interventions

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Chemotherapy & Immunotherapy Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison